Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I–associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-tac
Corresponding Author
Dr. Tanya J. Lehky MD
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Inc, Nutley, NJ
Human Immunodeficiency Virus Research Branch, Department of Acquired Immunodeficiency Syndrome, National Institute of Allergy and Infectious Diseases, Inc, Nutley, NJ
HIV Research Branch, DAIDS, NIAID, NIH, 6003 Executive Boulevard, Rockville, MD 20892Search for more papers by this authorMichael C. Levin MD
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Inc, Nutley, NJ
University of Tennessee, Memphis, TN
Search for more papers by this authorRyuji Kubota MD
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Inc, Nutley, NJ
Search for more papers by this authorRichard N. Bamford PhD
Metabolism Branch, National Cancer Institute, Bethesda, MD
Search for more papers by this authorAlfred N. Flerlage BA
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Inc, Nutley, NJ
Search for more papers by this authorSamantha S. Soldan BA
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Inc, Nutley, NJ
Search for more papers by this authorThomas P. Leist MD
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Inc, Nutley, NJ
Search for more papers by this authorAndrew Xavier MD
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Inc, Nutley, NJ
Human Immunodeficiency Virus Research Branch, Department of Acquired Immunodeficiency Syndrome, National Institute of Allergy and Infectious Diseases, Inc, Nutley, NJ
Search for more papers by this authorJeffrey D. White MD
Metabolism Branch, National Cancer Institute, Bethesda, MD
Search for more papers by this authorMargaret Brown MS
Immunology Laboratory, Clinical Center, National Institutes of Health, Bethesda, MD
Search for more papers by this authorThomas A. Fleisher MD
Immunology Laboratory, Clinical Center, National Institutes of Health, Bethesda, MD
Search for more papers by this authorLois E. Top RN
Metabolism Branch, National Cancer Institute, Bethesda, MD
Search for more papers by this authorHenry F. McFarland MD
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Inc, Nutley, NJ
Search for more papers by this authorThomas A. Waldmann MD
Metabolism Branch, National Cancer Institute, Bethesda, MD
Search for more papers by this authorSteven Jacobson PhD
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Inc, Nutley, NJ
Search for more papers by this authorCorresponding Author
Dr. Tanya J. Lehky MD
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Inc, Nutley, NJ
Human Immunodeficiency Virus Research Branch, Department of Acquired Immunodeficiency Syndrome, National Institute of Allergy and Infectious Diseases, Inc, Nutley, NJ
HIV Research Branch, DAIDS, NIAID, NIH, 6003 Executive Boulevard, Rockville, MD 20892Search for more papers by this authorMichael C. Levin MD
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Inc, Nutley, NJ
University of Tennessee, Memphis, TN
Search for more papers by this authorRyuji Kubota MD
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Inc, Nutley, NJ
Search for more papers by this authorRichard N. Bamford PhD
Metabolism Branch, National Cancer Institute, Bethesda, MD
Search for more papers by this authorAlfred N. Flerlage BA
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Inc, Nutley, NJ
Search for more papers by this authorSamantha S. Soldan BA
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Inc, Nutley, NJ
Search for more papers by this authorThomas P. Leist MD
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Inc, Nutley, NJ
Search for more papers by this authorAndrew Xavier MD
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Inc, Nutley, NJ
Human Immunodeficiency Virus Research Branch, Department of Acquired Immunodeficiency Syndrome, National Institute of Allergy and Infectious Diseases, Inc, Nutley, NJ
Search for more papers by this authorJeffrey D. White MD
Metabolism Branch, National Cancer Institute, Bethesda, MD
Search for more papers by this authorMargaret Brown MS
Immunology Laboratory, Clinical Center, National Institutes of Health, Bethesda, MD
Search for more papers by this authorThomas A. Fleisher MD
Immunology Laboratory, Clinical Center, National Institutes of Health, Bethesda, MD
Search for more papers by this authorLois E. Top RN
Metabolism Branch, National Cancer Institute, Bethesda, MD
Search for more papers by this authorHenry F. McFarland MD
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Inc, Nutley, NJ
Search for more papers by this authorThomas A. Waldmann MD
Metabolism Branch, National Cancer Institute, Bethesda, MD
Search for more papers by this authorSteven Jacobson PhD
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Inc, Nutley, NJ
Search for more papers by this authorAbstract
Human T-lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a neurological disease that results from an interaction of retroviral infection and immune activation. In this study, five doses (1 mg/kg) of humanized anti-Tac antibody were administered to 9 HAM/TSP patients at weeks 0,2,6,10, and 14. Preliminary immunological studies on HAM/TSP patients treated with humanized anti-Tac indicate that there is a selective down-regulation of activated T cells and a decrease in the HTLV-I viral load in peripheral blood lymphocytes, most likely through the selective removal of HTLV-I–infected, activated CD4+ lymphocytes.
References
- 1 Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; 2: 407–410
- 2
Osame M,
Usuku K,
Izumo S, et al.
HTLV-I associated myelopathy, a new clinical entity.
Lancet
1986;
2:
1031–1032
10.1016/S0140-6736(86)91298-5 Google Scholar
- 3 Poisez BJ, Ruscetti FW, Gazdar AR, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma Proc Natl Acad Sci USA 1980; 77: 7415–7419
- 4 Jacobson S, Raine CS, Mingioli ES, McFarlin DE. Isolation of an HTLV-I-like retrovirus from patients with tropical spastic paraparesis Nature 1988; 331: 540–543
- 5 Lehky TJ, Fox CH, Koenig S, et al. Detection of human T-lymphotropic virus type I (HTLV-I) tax RNA in the central nervous system of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by in situ hybridization. Ann Neurol 1995; 37: 167–175
- 6 Kira J, Itoyama Y, Koyanagi Y, et al. Presence of HTLV-I proviral DNA in central nervous system of patients with HTLV-I-associated myelopathy. Ann Neurol 1992; 31: 39–45
- 7 Inoue JI, Yoshida M, Seiki M. Transcriptional (p40x) and posttranscriptional (p27x−III) regulators are required for the expression and replication of human T cell leukemia virus type I Genes. Proc Natl Acad Sci USA 1987; 84: 3653–3657
- 8 Inoue J, Seiki M, Taniguchi T, et al. Induction of interleukin 2 receptor gene expression by p40x encoded by human T cell leukemia virus type I EMBO J 1986; 5: 2883–2888
- 9 Marcon L, Greenberg SJ, Nelson DL, et al. Soluble interleukin 2 receptor in human T cell leukemia virus type I infections: distinctions between tropical spastic paraparesis and adult T cell leukemia Clin Res 1988; 36: 443A (Abstract)
- 10 Jacobson S, Zaninovic V, Mora C, et al. Immunological findings in neurological diseases associated with antibodies to HTLV-I: activate lymphocytes in tropical spastic paraparesis. Ann Neurol 1988; 23 (Suppl): S196–S200
- 11 Itoyama Y, Minato S, Kira J, et al. Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy. Neurology 1988; 28: 1302–1307
- 12 Jacobson S, Shida H, McFarlin DE, et al. Circulating CD8+cytotoxic T-lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease Nature 1990; 348: 245–248
- 13 Maruyama M, Shibuya H, Harada H, et al. Evidence for aberrant activation of the interleukin 2 autocrine loop by HTLV-I encoded p40x and T3/T1 complex triggering Cell 1987; 48: 343–350
- 14 Tendler CL, Greenberg SJ, Blattner WA, et al. Transactivation of interleukin 2 and its receptor induces immune activation in human T lymphotropic virus type I-associated myelopathy: pathological implications and a rationale for immunotherapy Proc Natl Acad Sci USA 1990; 87: 5218–5222
- 15 Gout O, Gessain A, Iba-Zizen M, et al. The effect of zidovudine on chronic myelopathy associated with HTLV-I J Neurol 1991; 238: 108–109 (Letter)
- 16 Sheremata WA, Benedict D, Squilacote DC, et al. High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible effecacy. Neurology 1993; 43: 2125–2129
- 17 Osame M, Igata A, Matsumoto M, et al. HTLV-I associated myelopathy (HAM): treatment trials, retrospective survey, and clinical and laboratory findings. Hematol Rev 1990; 37: 271–284
- 18 Kira J, Fujihara K, Itoyama Y, et al. Leukoencephalopathy in HTLV-I associated myelopathy/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy. J Neurol Sci 1991; 106: 41–49
- 19 Kuroda Y, Takashima H, Ikeda A, et al. Treatment of HTLV-I associated myelopathy with high-dose intravenous gammaglobulin. J Neurol 1991; 238: 309–314
- 20 Harrington WJ, Sheremata WA, Snodgrass SR, et al. Tropical spastic paraparesis/HTLV-I associated myelopathy (TSP/HAM) treatment with an anabolic steroid Danazol. AIDS Res Hum Retrovirus 1991; 7: 1031–1034
- 21 Kataoka A, Imai H, Inayoshi S, Tsuda T. Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy J Neurol Neurosurg Psychiatry 1993; 56: 1213–1216
- 22 Shibayama K, Nakamura T, Nagasato K, et al. Interferon-alpha treatment in HTLV-I-associated myelopathy: studies in clinical and immunological aspects. J Neurol Sci 1991; 106: 186–192
- 23 Matsuo H, Nakamura T, Tsujihata M, et al. Human T-lymphotropic virus type I (HTLV-I) associated myelopathy in Nagasaki: clinical features and treatment of 21 cases. Jpn J Med 1989; 28: 328–334
- 24 Junghans RP, Waldmann TA, Landolfi NF, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders Cancer Res 1990; 50: 1495–1502
- 25 Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotropic virus I-induced adult T-cell leukemia Blood 1993; 82: 1701–1712
- 26 Waldmann TA, Goldman CK, Bongiovanni KF, et al. Therapy of patients with human T-cell lymphotropic virus I-induced adult T-cell leukemia with anti-tac, a monoclonal antibody to the receptor for interleukin-2. Blood 1988; 72: 1805–1816
- 27 Vincenti F, Kirkman R, Light S, et al. Interleukin-2 receptor blockade with Daclizumab to prevent acute renal rejection in renal transplantation N Engl J Med 1998; 338: 161–165
- 28 Scientific Group on ATLV-I Infections and Its Association Disease. Manila, Philippines: Office for the Western Pacific of the World Health Organization, March 1989
- 29 Hakimi J, Chizzonite R, Luke DR, et al. Reduced immunogenicity and improved pharmacokinetics of humanized anti-tac in cynomologous monkeys. J Immunol 1991; 147: 1352–1359
- 30 Fleisher TA. Phenotypic analysis of mononuclear leucytes by flow cytometry. Immunol Allergy Clin North Am 1994; 14: 225–240
Citing Literature
